Azithromycin and dentistry - A useful agent?

British Dental Journal

Volumn 197, Issue 3, 2004, Pages 141-143

  Addy, L D ^a   Martin, M V ^b  

^a UNIVERSITY DENTAL HOSPITAL   (United Kingdom)

^b LIVERPOOL UNIVERSITY DENTAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; VANCOMYCIN;

ABSORPTION; CLINICAL TRIAL; DENTISTRY; DRUG EFFICACY; ENDOCARDITIS; HUMAN; MEDICAL LITERATURE; NONHUMAN; PH MEASUREMENT; PROPHYLAXIS; REVIEW;

ADOLESCENT; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZITHROMYCIN; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DENTAL CARE; DENTAL CARE FOR CHRONICALLY ILL; ENDOCARDITIS, BACTERIAL; HUMANS; MIDDLE AGED; MOUTH DISEASES; TOOTH DISEASES;

EID: 4444300666     PISSN: 00070610     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bdj.4811530     Document Type: Review

References (39)

1. Littler W A. Clindamycin suspension and endocarditis prophylaxis. Br Dent J 2001; 190: 407.
2. Capitano B, Quintiliani R, Nightingale C H, Nicolau D P. Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children. Paediatr Drugs 2001; 3: 703-718.
3. Dajani A S, Taubert K A, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation 1997; 96: 358-366.
4. Wilson J T, van Boxtel C J. Pharmacokinetics of Erythromycin in man. Antibiot Chemother 1978; 25: 181-203.
5. Washington J A 2nd, Wilson W R. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). Mayo Clin Proc 1985; 60: 271-278.
6. Chun A, Seitz J. Pharmokinetics and biological availability of erythromycin. Infection 1977; 5(Suppl 1): 14-22.
7. Lode H, Borner K, Koeppe P, Scaberg T. Azithromycin- review of key chemical, pharmokinetic and microbiological features. J Antimicrob Chemother 1996; 37 (Suppl C): 1-8.
8. Fiese E F, Steffen S H. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990; 25 Suppl A: 39-47.
9. Coulter W A, McGimpsey J G, Coffey A, Strawbridge J, Linden G J. Dental anxiety and the absorption of orally administered erythromycin stearate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 80: 660-665.
10. Sefton A M, Maskell J P, Kerawala C, et al. Comparative efficacy and tolerance of erythromycin and josamycin in the prevention of bacteraemia following dental extraction. J Antimicrob Chemother 1990; 25: 975-984.
11. Shanson D C, McNabb W R, Ruby K. High dose oral erythromycin for preventing endocarditis. Lancet 1983; 1: 299-300.
12. Gladue R P, Bright G M, Isaacson R E, Newborg M F. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277-282.
13. Gladue R P, Snider M E. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990; 34: 1056-1060.
14. Bonnet M, Van der Auwera P. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP- 62,993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob Agents Chemother 1992; 36: 1302-1309.
15. Foulds G, Shepard R M, Johnson R B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 (Suppl A): 73-82.
16. Foulds G, Johnson R B. Selection of dose regimens of azithromycin. J Antimicrob Chemother 1993; 31 (Suppl E): 39-50.
17. Foulds G, Luke D R, Teng R, Willavize S A, Friedman H, Curatolo W J. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996; 37 (Suppl C): 37-44.
18. Tsitasika A, Pefanis A, Perdikaris G S, Donta I, Karayiannakos P, Giamarellou H. Single-oral dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis. Antimicrob Agents Chemother 2000; 44: 1754-1756.
19. Girard A E, Cimochowski C R, Faiella J A. The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections. J Antimicrob Chemother 1993; 31 (Suppl E): 29-37.
20. Rouse M S, Steckelberg J M, Brandt C M, Patel R, Miro J M, Wilson W R. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. Antimicrob Agents Chemother 1997; 41: 1673-1676.
21. Marsh P, Martin M. Oral Microbiology. 4th ed. Oxford: Wright, 1999.
22. Seymour R A, Lowry R, Whitworth J M, Martin M V. Infective endocarditis, dentistry and antibiotic prophylaxis; time for a rethink? Br Dent J 2000; 189: 610-616.
23. Lo Bue A M, Sammartino R, Chisari G, Gismondo M R, Nicoletti G. Efficacy of azithromycin compared with spiramycin in the treatment of odontogenic infections. J Antimicrob Chemother 1993; 31 (Suppl E): 119-127.
24. Clement P A, de Gandt J B. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults. J Int Med Res 1998; 26: 66-75.
25. Sefton A M, Maskell J P, Beighton D, et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 1996; 23: 998-1003.
26. Malizia T, Tejada M R, Ghelardi E, et al. Periodontal tissue disposition of azithromycin. J Periodontol 1997; 68: 1206-1209.
27. Malizia T, Batoni G, Ghelardi E, et al. Interaction between piroxicam and azithromycin during distribution to human periodontal tissues. J Periodontol 2001; 72: 1151-1156.
28. Varvara G, D'Arcangelo C. [The evaluation of the clinical efficacy and tolerance of azithromycin in odontostomatological infections]. Minerva Stomatol 1998; 47: 57-62.
29. Blandizzi C, Malizia T, Lupetti A, et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 1999; 70: 960-966.
30. Williams J D, Maskell J P, Shain H, et al. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother 1992; 30: 27-37.
31. Peters D H, Friedel H A, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750-799.
32. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993; 31 (Suppl E): 111-117.
33. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; 91: 40S-45S.
34. Smith S R, Foyle D M, Daniels J, et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis in adults: clinical results. J Clin Periodontol 2002; 29: 54-61.
35. Maskell J P, Sefton A M, Cannell H, et al. Predominance of resistant oral streptococci in saliva and the effect of a single course of josamycin or erythromycin. J Antimicrob Chemother 1990; 26: 539-548.
36. Harrison G A, Stross W P, Rubin M P, Davies R M, Speller D C. Resistance in oral streptococci after repeated three-dose erythromycin prophylaxis. J Antimicrob Chemother 1985; 15: 471-479.
37. Sprunt K, Leidy G, Redman W. Cross resistance between lincomycin and erythromycin in viridans streptococci. Pediatrics 1970; 46: 84-88.
38. LeBlanc D J, Hawley R J, Lee L N, St Martin E J. 'Conjugal' transfer of plasmid DNA among oral streptococci. Proc Natl Acad Sci USA 1978; 75: 3484-3487.
39. Dental Practitioners' Formulary. 2002-2004. British National Formulary Number 44. London: The Royal Pharmaceutical Society of Great Britain and The British Medical Association, 2002.